Objectives ⢠New drug approval process ⢠Pricing of new drugs ⢠Off ...
Objectives ⢠New drug approval process ⢠Pricing of new drugs ⢠Off ...
Objectives ⢠New drug approval process ⢠Pricing of new drugs ⢠Off ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
3/15/13%<br />
25.0<br />
National Health Expenditures as a Share <strong>of</strong><br />
Gross Domestic Product (GDP) to 2008<br />
Projection<br />
% <strong>of</strong> GDP<br />
20.0<br />
15.0<br />
10.0<br />
5.0<br />
0.0<br />
1960<br />
1962<br />
1964<br />
1966<br />
1968<br />
1970<br />
1972<br />
1974<br />
1976<br />
1978<br />
1980<br />
1982<br />
1984<br />
1986<br />
1988<br />
1990<br />
1992<br />
Source: CMS, <strong>Off</strong>ice <strong>of</strong> the Actuary, National Health Statistics Group.<br />
1994<br />
1996<br />
1998<br />
2000<br />
2002<br />
2004<br />
2006<br />
2008<br />
2010<br />
2012<br />
2014<br />
2016<br />
2018<br />
2020<br />
The Value Decision<br />
Unattractive<br />
The “Easy<br />
No” (More<br />
expensive and<br />
less effective)<br />
Standard<br />
<strong>of</strong> care<br />
The Dilemma<br />
(Less expensive<br />
and less effective)<br />
Change in costs<br />
The Challenge<br />
(More expensive<br />
and more<br />
effective)<br />
Change in effects<br />
The “Easy<br />
Yes” (Less<br />
expensive and<br />
more effective)<br />
Value<br />
Threshold<br />
Attractive<br />
The <strong>Pricing</strong> Channel:<br />
Cost vs. Clinical Value<br />
Cost per Course <strong>of</strong> Therapy<br />
Trend Line<br />
90% confidence limits<br />
Ref.:%Easton%Associates,%LLC%<br />
Clinical Value<br />
15%
Change language